Key result
High-dose mitoxantrone yields a ~22% response rate but causes cardiotoxicity in metastatic breast cancer.
Answers are grounded in this paper and cite their sources.
Limited single-agent activity in metastatic breast cancer; leaves open evaluation in combinations or selected subgroups.
Twenty-seven women with metastatic breast cancer were treated with mitoxantrone as a single agent, with the use of an intensive dose-escalating schedule. Doses were given at 0.5 mg/m2/day as an iv injection for 3 consecutive days and then were escalated each month by 2.5 mg/m2/day until maximal tolerance was reached on the basis of hematologic or cardiac toxicity. No complete responses were demonstrated. Six patients (22%) had partial responses of 5.5 months' median duration. Four of 12 patients who had not received prior doxorubicin responded (33%), whereas two of 15 patients with previous doxorubicin exposure responded (13%). Cardiotoxicity, determined by serial radionuclide ventriculography, occurred in 10 patients (37%) at a mean total mitoxantrone dose of 83.0 mg/m2. Three of these 10 patients had no predisposing risk factors, four had received thoracic radiotherapy that might have involved the heart, and three had received prior doxorubicin without clinical toxicity. The failure of dose intensification to augment the response rate when compared to the response rates reported for less myelotoxic doses of the drug, in addition to the extent of cardiotoxicity noted, calls into question the value of dose intensification of mitoxantrone in the treatment of metastatic breast cancer.
No takes yet. Share an insight, caveat, or question.
Shpall et al. (1988) studied Metastatic breast cancer (n=27). Mitoxantrone was evaluated on Objective tumor response (partial response rate). Intensive dose-escalating mitoxantrone yielded a 22% partial response rate and caused cardiotoxicity in 37% of women with metastatic breast cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: